GlassScriptPhysician profile
Mathew A Strasser
NPI 1164447884
$2,071.00
in general payments reported to CMS, 2019-2025
30 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2021: $106 · 2022: $355 · 2023: $390 · 2024: $697 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445 · Education: $58.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.16 |
| Education | $58.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $223.68 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $193.07 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $178.73 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $175.04 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.98 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $138.26 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $104.20 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $86.25 | 2024-2025 | Rexulti |
| Pfizer INC. | $78.55 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.98 | 2024 | Trintellix |
| Amgen INC. | $69.53 | 2022-2024 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $66.14 | 2019-2023 | Wegovy |
| Abbott Laboratories | $62.85 | 2023-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $62.71 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $58.44 | 2023-2025 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $52.18 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $48.54 | 2024 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $40.56 | 2021-2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $26.32 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Eisai INC. | $17.51 | 2022 | |
| Viiv Healthcare Company | $16.02 | 2025 | Apretude |
| Regeneron Healthcare Solutions, INC. | $14.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.24 | 2019 | |
| Biogen, INC. | $13.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.75 | 2022 | |
| Edwards Lifesciences Corporation | $13.28 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Dynavax Technologies Corporation | $12.90 | 2024 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $12.75 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Strasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.